Johnson & Johnson COVID-19 vaccine generates immune response in trial

Johnson & Johnson’s coronavirus vaccine generated a lasting immune response to the deadly bug in an early-stage clinical trial, the pharmaceutical giant said.

More than 90 percent of the study’s 805 participants had neutralizing antibodies offering protection against COVID-19 29 days after receiving a single dose of the vaccine, the New Jersey-based drugmaker said Wednesday.

The antibodies stuck around for at least 71 days among the participants ranging in age from…

Click here to view the original article.

Show More

Related Articles

Back to top button